Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Pachón J[au]:

Optimizing the Clinical Use of Vancomycin. Álvarez R et al. Antimicrob Agents Chemother. (2016)

Perspectives for clinical use of engineered human host defense antimicrobial peptides. Pachón-Ibáñez ME et al. FEMS Microbiol Rev. (2017)

Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. McConnell MJ et al. FEMS Microbiol Rev. (2013)

Search results

Items: 1 to 50 of 259

1.

Prevalence and clinical impact of Streptococcus pneumoniae nasopharyngeal carriage in solid organ transplant recipients.

Roca-Oporto C, Cebrero-Cangueiro T, Gil-Marqués ML, Labrador-Herrera G, Smani Y, González-Roncero FM, Marín LM, Pachón J, Pachón-Ibáñez ME, Cordero E.

BMC Infect Dis. 2019 Aug 6;19(1):697. doi: 10.1186/s12879-019-4321-8.

2.

The anthelmintic oxyclozanide restores the activity of colistin against colistin-resistant Gram-negative bacilli.

Ayerbe-Algaba R, Gil-Marqués ML, Miró-Canturri A, Parra-Millán R, Pachón-Ibáñez ME, Jiménez-Mejías ME, Pachón J, Smani Y.

Int J Antimicrob Agents. 2019 Jul 9. pii: S0924-8579(19)30186-4. doi: 10.1016/j.ijantimicag.2019.07.006. [Epub ahead of print]

PMID:
31299296
3.

Relationship Between Different Resistance Mechanisms and Virulence in Acinetobacter baumannii.

Espinal P, Pantel A, Rolo D, Marti S, López-Rojas R, Smani Y, Pachón J, Vila J, Lavigne JP.

Microb Drug Resist. 2019 Jun;25(5):752-760. doi: 10.1089/mdr.2018.0182. Epub 2019 Jan 11.

PMID:
30632884
4.

Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections.

Marrugal-Lorenzo JA, Serna-Gallego A, Berastegui-Cabrera J, Pachón J, Sánchez-Céspedes J.

Sci Rep. 2019 Jan 9;9(1):17. doi: 10.1038/s41598-018-37290-3.

5.

Relationship Between the Quorum Network (Sensing/Quenching) and Clinical Features of Pneumonia and Bacteraemia Caused by A. baumannii.

Fernandez-Garcia L, Ambroa A, Blasco L, Bleriot I, López M, Alvarez-Marin R, Fernández-Cuenca F, Martinez-Martinez L, Vila J, Rodríguez-Baño J, Garnacho-Montero J, Cisneros JM, Pascual A, Pachón J, Bou G, Smani Y, Tomás M.

Front Microbiol. 2018 Dec 17;9:3105. doi: 10.3389/fmicb.2018.03105. eCollection 2018.

6.

In vitro Activity of Pentamidine Alone and in Combination With Aminoglycosides, Tigecycline, Rifampicin, and Doripenem Against Clinical Strains of Carbapenemase-Producing and/or Colistin-Resistant Enterobacteriaceae.

Cebrero-Cangueiro T, Álvarez-Marín R, Labrador-Herrera G, Smani Y, Cordero-Matía E, Pachón J, Pachón-Ibáñez ME.

Front Cell Infect Microbiol. 2018 Oct 18;8:363. doi: 10.3389/fcimb.2018.00363. eCollection 2018.

7.

Synergistic Activity of Niclosamide in Combination With Colistin Against Colistin-Susceptible and Colistin-Resistant Acinetobacter baumannii and Klebsiella pneumoniae.

Ayerbe-Algaba R, Gil-Marqués ML, Jiménez-Mejías ME, Sánchez-Encinales V, Parra-Millán R, Pachón-Ibáñez ME, Pachón J, Smani Y.

Front Cell Infect Microbiol. 2018 Oct 3;8:348. doi: 10.3389/fcimb.2018.00348. eCollection 2018.

8.

Inhibition of adenovirus infection by mifepristone.

Marrugal-Lorenzo JA, Serna-Gallego A, González-González L, Buñuales M, Poutou J, Pachón J, Gonzalez-Aparicio M, Hernandez-Alcoceba R, Sánchez-Céspedes J.

Antiviral Res. 2018 Nov;159:77-83. doi: 10.1016/j.antiviral.2018.09.011. Epub 2018 Sep 27.

PMID:
30268911
9.

Synergistic activity of an OmpA inhibitor and colistin against colistin-resistant Acinetobacter baumannii: mechanistic analysis and in vivo efficacy.

Parra-Millán R, Vila-Farrés X, Ayerbe-Algaba R, Varese M, Sánchez-Encinales V, Bayó N, Pachón-Ibáñez ME, Teixidó M, Vila J, Pachón J, Giralt E, Smani Y.

J Antimicrob Chemother. 2018 Dec 1;73(12):3405-3412. doi: 10.1093/jac/dky343.

PMID:
30188994
10.

Peptidoglycan recycling contributes to intrinsic resistance to fosfomycin in Acinetobacter baumannii.

Gil-Marqués ML, Moreno-Martínez P, Costas C, Pachón J, Blázquez J, McConnell MJ.

J Antimicrob Chemother. 2018 Nov 1;73(11):2960-2968. doi: 10.1093/jac/dky289.

PMID:
30124902
11.

Effect of Hypoxia on the Pathogenesis of Acinetobacter baumannii and Pseudomonas aeruginosa In Vitro and in Murine Experimental Models of Infection.

Gil-Marqués ML, Pachón-Ibáñez ME, Pachón J, Smani Y.

Infect Immun. 2018 Sep 21;86(10). pii: e00543-18. doi: 10.1128/IAI.00543-18. Print 2018 Oct.

12.

Multiple Multicomponent Reactions: Unexplored Substrates, Selective Processes, and Versatile Chemotypes in Biomedicine.

Ghashghaei O, Caputo S, Sintes M, Revés M, Kielland N, Estarellas C, Luque FJ, Aviñó A, Eritja R, Serna-Gallego A, Marrugal-Lorenzo JA, Pachón J, Sánchez-Céspedes J, Treadwell R, de Moliner F, Vendrell M, Lavilla R.

Chemistry. 2018 Sep 25;24(54):14513-14521. doi: 10.1002/chem.201802877. Epub 2018 Aug 28.

PMID:
29974986
13.

Immunization with lipopolysaccharide-free outer membrane complexes protects against Acinetobacter baumannii infection.

Pulido MR, García-Quintanilla M, Pachón J, McConnell MJ.

Vaccine. 2018 Jul 5;36(29):4153-4156. doi: 10.1016/j.vaccine.2018.05.113. Epub 2018 Jun 7.

PMID:
29887323
14.

Efficacy of Colistin and Its Combination With Rifampin in Vitro and in Experimental Models of Infection Caused by Carbapenemase-Producing Clinical Isolates of Klebsiella pneumoniae.

Pachón-Ibáñez ME, Labrador-Herrera G, Cebrero-Cangueiro T, Díaz C, Smani Y, Del Palacio JP, Rodríguez-Baño J, Pascual A, Pachón J, Conejo MC.

Front Microbiol. 2018 May 15;9:912. doi: 10.3389/fmicb.2018.00912. eCollection 2018.

15.

Phenotypic changes associated with Colistin resistance due to Lipopolysaccharide loss in Acinetobacter baumannii.

Carretero-Ledesma M, García-Quintanilla M, Martín-Peña R, Pulido MR, Pachón J, McConnell MJ.

Virulence. 2018 Dec 31;9(1):930-942. doi: 10.1080/21505594.2018.1460187.

16.

Intracellular Trafficking and Persistence of Acinetobacter baumannii Requires Transcription Factor EB.

Parra-Millán R, Guerrero-Gómez D, Ayerbe-Algaba R, Pachón-Ibáñez ME, Miranda-Vizuete A, Pachón J, Smani Y.

mSphere. 2018 Mar 28;3(2). pii: e00106-18. doi: 10.1128/mSphere.00106-18. eCollection 2018 Mar-Apr.

17.

Combating virulence of Gram-negative bacilli by OmpA inhibition.

Vila-Farrés X, Parra-Millán R, Sánchez-Encinales V, Varese M, Ayerbe-Algaba R, Bayó N, Guardiola S, Pachón-Ibáñez ME, Kotev M, García J, Teixidó M, Vila J, Pachón J, Giralt E, Smani Y.

Sci Rep. 2017 Oct 31;7(1):14683. doi: 10.1038/s41598-017-14972-y.

18.

Erratum for Martínez-Florensa et al., "Protective Effects of Human and Mouse Soluble Scavenger-Like CD6 Lymphocyte Receptor in a Lethal Model of Polymicrobial Sepsis".

Martínez-Florensa M, Consuegra-Fernández M, Aranda F, Armiger-Borràs N, Di Scala M, Carrasco E, Pachón J, Vila J, González-Aseguinolaza G, Lozano F.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01997-17. doi: 10.1128/AAC.01997-17. Print 2017 Nov. No abstract available.

19.

Heteroresistance to Piperacillin-Tazobactam in Clinical Isolates of Escherichia coli Sequence Type 131.

Rodríguez-Villodres Á, Ortiz de la Rosa JM, Álvarez-Marín R, Pachón J, Aznar J, Lepe JA, Smani Y.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01923-17. doi: 10.1128/AAC.01923-17. Print 2018 Jan. No abstract available.

20.

Perspectives for clinical use of engineered human host defense antimicrobial peptides.

Pachón-Ibáñez ME, Smani Y, Pachón J, Sánchez-Céspedes J.

FEMS Microbiol Rev. 2017 May 1;41(3):323-342. doi: 10.1093/femsre/fux012. Review.

21.

Overproduction of Outer Membrane Protein A by Acinetobacter baumannii as a Risk Factor for Nosocomial Pneumonia, Bacteremia, and Mortality Rate Increase.

Sánchez-Encinales V, Álvarez-Marín R, Pachón-Ibáñez ME, Fernández-Cuenca F, Pascual A, Garnacho-Montero J, Martínez-Martínez L, Vila J, Tomás MM, Cisneros JM, Bou G, Rodríguez-Baño J, Pachón J, Smani Y.

J Infect Dis. 2017 Mar 15;215(6):966-974. doi: 10.1093/infdis/jix010.

PMID:
28453834
22.

Pathogenic Acinetobacter species have a functional type I secretion system and contact-dependent inhibition systems.

Harding CM, Pulido MR, Di Venanzio G, Kinsella RL, Webb AI, Scott NE, Pachón J, Feldman MF.

J Biol Chem. 2017 Jun 2;292(22):9075-9087. doi: 10.1074/jbc.M117.781575. Epub 2017 Apr 3.

23.

Efficacy of ceftaroline versus vancomycin in an experimental foreign-body and systemic infection model caused by biofilm-producing methicillin-resistant Staphylococcus epidermidis.

Domínguez-Herrera J, López-Rojas R, Smani Y, Labrador-Herrera G, Pachón J.

Int J Antimicrob Agents. 2016 Dec;48(6):661-665. doi: 10.1016/j.ijantimicag.2016.09.011. Epub 2016 Oct 18.

PMID:
28128094
24.

Colistin Dosage without Loading Dose Is Efficacious when Treating Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia Caused by Strains with High Susceptibility to Colistin.

Álvarez-Marín R, López-Rojas R, Márquez JA, Gómez MJ, Molina J, Cisneros JM, Ortiz-Leyba C, Aznar J, Garnacho-Montero J, Pachón J.

PLoS One. 2016 Dec 19;11(12):e0168468. doi: 10.1371/journal.pone.0168468. eCollection 2016.

25.

Protective Effects of Human and Mouse Soluble Scavenger-Like CD6 Lymphocyte Receptor in a Lethal Model of Polymicrobial Sepsis.

Martínez-Florensa M, Consuegra-Fernández M, Aranda F, Armiger-Borràs N, Di Scala M, Carrasco E, Pachón J, Vila J, González-Aseguinolaza G, Lozano F.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01391-16. doi: 10.1128/AAC.01391-16. Print 2017 Jan. Erratum in: Antimicrob Agents Chemother. 2017 Oct 24;61(11):.

26.

Genomic Evolution of Two Acinetobacter baumannii Clinical Strains from ST-2 Clones Isolated in 2000 and 2010 (ST-2_clon_2000 and ST-2_clon_2010).

López M, Rueda A, Florido JP, Blasco L, Gato E, Fernández-García L, Martínez-Martínez L, Fernández-Cuenca F, Pachón J, Cisneros JM, Garnacho-Montero J, Vila J, Rodríguez-Baño J, Pascual A, Bou G, Tomás M.

Genome Announc. 2016 Oct 20;4(5). pii: e01182-16. doi: 10.1128/genomeA.01182-16.

27.

Inhibition of LpxC Increases Antibiotic Susceptibility in Acinetobacter baumannii.

García-Quintanilla M, Caro-Vega JM, Pulido MR, Moreno-Martínez P, Pachón J, McConnell MJ.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):5076-9. doi: 10.1128/AAC.00407-16. Print 2016 Aug.

28.

New 4-Acyl-1-phenylaminocarbonyl-2-phenylpiperazine Derivatives as Potential Inhibitors of Adenovirus Infection. Synthesis, Biological Evaluation, and Structure-activity Relationships.

Sánchez-Céspedes J, Martínez-Aguado P, Vega-Holm M, Serna-Gallego A, Candela JI, Marrugal-Lorenzo JA, Pachón J, Iglesias-Guerra F, Vega-Pérez JM.

J Med Chem. 2016 Jun 9;59(11):5432-48. doi: 10.1021/acs.jmedchem.6b00300. Epub 2016 May 31.

PMID:
27195951
29.

Impaired growth under iron-limiting conditions associated with the acquisition of colistin resistance in Acinetobacter baumannii.

López-Rojas R, García-Quintanilla M, Labrador-Herrera G, Pachón J, McConnell MJ.

Int J Antimicrob Agents. 2016 Jun;47(6):473-7. doi: 10.1016/j.ijantimicag.2016.03.010. Epub 2016 Apr 22.

PMID:
27179817
30.

Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival.

de Miguel-Luken MJ, Chaves-Conde M, Quintana B, Menoyo A, Tirado I, de Miguel-Luken V, Pachón J, Chinchón D, Suarez V, Carnero A.

Oncotarget. 2016 May 31;7(22):31723-37. doi: 10.18632/oncotarget.9172.

31.

Efficacy of Lysophosphatidylcholine in Combination with Antimicrobial Agents against Acinetobacter baumannii in Experimental Murine Peritoneal Sepsis and Pneumonia Models.

Parra Millán R, Jiménez Mejías ME, Sánchez Encinales V, Ayerbe Algaba R, Gutiérrez Valencia A, Pachón Ibáñez ME, Díaz C, Pérez Del Palacio J, López Cortés LF, Pachón J, Smani Y.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4464-70. doi: 10.1128/AAC.02708-15. Print 2016 Aug.

32.

New molecules and adjuvants in the treatment of infections by Acinetobacter baumannii.

Smani Y, Pachón-Ibáñez ME, Pachón J.

Expert Opin Pharmacother. 2016 Jun;17(9):1207-14. doi: 10.1080/14656566.2016.1176144. Epub 2016 Apr 28. Review.

PMID:
27067283
33.

Draft Genome Sequences of Seven Multidrug-Resistant Acinetobacter baumannii Strains, Isolated from Respiratory Samples in Spain.

Labrador-Herrera G, Álvarez R, López-Rojas R, Smani Y, Cebrero-Cangueiro T, Rueda A, Pérez Florido J, Pachón J, Pachón-Ibáñez ME.

Genome Announc. 2016 Mar 31;4(2). pii: e00083-16. doi: 10.1128/genomeA.00083-16.

34.

Optimizing the Clinical Use of Vancomycin.

Álvarez R, López Cortés LE, Molina J, Cisneros JM, Pachón J.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2601-9. doi: 10.1128/AAC.03147-14. Print 2016 May. Review.

35.

Use of adjuvants in the treatment of Acinetobacter baumannii.

Pachón-Ibáñez ME, Smani Y, Pachón J.

Expert Rev Anti Infect Ther. 2016;14(2):153-5. doi: 10.1586/14787210.2016.1126508. Epub 2015 Dec 19.

PMID:
26620637
36.

Reduced susceptibility to biocides in Acinetobacter baumannii: association with resistance to antimicrobials, epidemiological behaviour, biological cost and effect on the expression of genes encoding porins and efflux pumps.

Fernández-Cuenca F, Tomás M, Caballero-Moyano FJ, Bou G, Martínez-Martínez L, Vila J, Pachón J, Cisneros JM, Rodríguez-Baño J, Pascual Á; Spanish Group of Nosocomial Infections (GEIH) from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI); Spanish Group of Nosocomial Infections GEIH from the Spanish Society of Clinical Microbiology and Infectious Diseases SEIMC and the Spanish Network for Research in Infectious Diseases REIPI.

J Antimicrob Chemother. 2015 Dec;70(12):3222-9. doi: 10.1093/jac/dkv262. Epub 2015 Sep 10.

PMID:
26517560
37.

Lipopolysaccharide loss produces partial colistin dependence and collateral sensitivity to azithromycin, rifampicin and vancomycin in Acinetobacter baumannii.

García-Quintanilla M, Carretero-Ledesma M, Moreno-Martínez P, Martín-Peña R, Pachón J, McConnell MJ.

Int J Antimicrob Agents. 2015 Dec;46(6):696-702. doi: 10.1016/j.ijantimicag.2015.07.017. Epub 2015 Sep 7.

PMID:
26391380
38.

Chronotropic incompetence in Chagas disease: usefulness of dual sensor pacemaker based on volume minute and accelerometer.

Pachón JC.

Rev Bras Cir Cardiovasc. 2015 Jul-Sep;30(3):III-VI. doi: 10.5935/1678-9741.20150011. No abstract available.

39.

Sequence-activity relationship, and mechanism of action of mastoparan analogues against extended-drug resistant Acinetobacter baumannii.

Vila-Farrés X, López-Rojas R, Pachón-Ibáñez ME, Teixidó M, Pachón J, Vila J, Giralt E.

Eur J Med Chem. 2015 Aug 28;101:34-40. doi: 10.1016/j.ejmech.2015.06.016. Epub 2015 Jun 9.

40.

Therapeutic efficacy of lysophosphatidylcholine in severe infections caused by Acinetobacter baumannii.

Smani Y, Domínguez-Herrera J, Ibáñez-Martínez J, Pachón J.

Antimicrob Agents Chemother. 2015 Jul;59(7):3920-4. doi: 10.1128/AAC.04986-14. Epub 2015 Apr 20.

41.

MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer.

de Miguel-Luken MJ, Chaves-Conde M, de Miguel-Luken V, Muñoz-Galván S, López-Guerra JL, Mateos JC, Pachón J, Chinchón D, Suarez V, Carnero A.

Oncotarget. 2015 May 20;6(14):12625-36.

42.

Immunization with lipopolysaccharide-deficient whole cells provides protective immunity in an experimental mouse model of Acinetobacter baumannii infection.

García-Quintanilla M, Pulido MR, Pachón J, McConnell MJ.

PLoS One. 2014 Dec 8;9(12):e114410. doi: 10.1371/journal.pone.0114410. eCollection 2014.

43.

Comparing multipollutant emissions-based mobile source indicators to other single pollutant and multipollutant indicators in different urban areas.

Oakes MM, Baxter LK, Duvall RM, Madden M, Xie M, Hannigan MP, Peel JL, Pachon JE, Balachandran S, Russell A, Long TC.

Int J Environ Res Public Health. 2014 Nov 14;11(11):11727-52. doi: 10.3390/ijerph111111727.

44.

Atrial fibrillation ablation in systolic dysfunction: clinical and echocardiographic outcomes.

Lobo TJ, Pachon CT, Pachon JC, Pachon EI, Pachon MZ, Pachon JC, Santillana TG, Zerpa JC, Albornoz RN, Jatene AD.

Arq Bras Cardiol. 2015 Jan;104(1):45-52. doi: 10.5935/abc.20140167. Epub 2014 Nov 11. English, Portuguese.

45.

Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort.

López-Cortés LE, Cisneros JM, Fernández-Cuenca F, Bou G, Tomás M, Garnacho-Montero J, Pascual A, Martínez-Martínez L, Vila J, Pachón J, Rodríguez Baño J; GEIH/REIPI-Ab2010 Group.

J Antimicrob Chemother. 2014 Nov;69(11):3119-26. doi: 10.1093/jac/dku233. Epub 2014 Jun 25.

PMID:
24970742
46.

Characterization of plasmids carrying the blaOXA-24/40 carbapenemase gene and the genes encoding the AbkA/AbkB proteins of a toxin/antitoxin system.

Mosqueda N, Gato E, Roca I, López M, de Alegría CR, Fernández Cuenca F, Martínez-Martínez L, Pachón J, Cisneros JM, Rodríguez-Baño J, Pascual A, Vila J, Bou G, Tomás M; GEIH-GEMARA (SEIMC) and REIPI.

J Antimicrob Chemother. 2014 Oct;69(10):2629-33. doi: 10.1093/jac/dku179. Epub 2014 May 30.

PMID:
24879663
47.

Characterization of protective extracellular membrane-derived vesicles produced by Streptococcus pneumoniae.

Olaya-Abril A, Prados-Rosales R, McConnell MJ, Martín-Peña R, González-Reyes JA, Jiménez-Munguía I, Gómez-Gascón L, Fernández J, Luque-García JL, García-Lidón C, Estévez H, Pachón J, Obando I, Casadevall A, Pirofski LA, Rodríguez-Ortega MJ.

J Proteomics. 2014 Jun 25;106:46-60. doi: 10.1016/j.jprot.2014.04.023. Epub 2014 Apr 24.

PMID:
24769240
48.

Activity of host antimicrobials against multidrug-resistant Acinetobacter baumannii acquiring colistin resistance through loss of lipopolysaccharide.

García-Quintanilla M, Pulido MR, Moreno-Martínez P, Martín-Peña R, López-Rojas R, Pachón J, McConnell MJ.

Antimicrob Agents Chemother. 2014 May;58(5):2972-5. doi: 10.1128/AAC.02642-13. Epub 2014 Feb 24.

49.

Role of OmpA in the multidrug resistance phenotype of Acinetobacter baumannii.

Smani Y, Fàbrega A, Roca I, Sánchez-Encinales V, Vila J, Pachón J.

Antimicrob Agents Chemother. 2014;58(3):1806-8. doi: 10.1128/AAC.02101-13. Epub 2013 Dec 30.

50.

Assessing usability, label comprehension, pen robustness and pharmacokinetics of a self-administered prefilled autoinjector pen of methotrexate in patients with rheumatoid arthritis.

Pachon JA, Kivitz AJ, Heuer KU, Pichlmeier U.

SAGE Open Med. 2014 Dec 22;2:2050312114564241. doi: 10.1177/2050312114564241. eCollection 2014.

Supplemental Content

Loading ...
Support Center